Symptoms: During controlled clinical trials in healthy subjects, single doses of up to 600mg linagliptin (equivalent to 120 times the recommended dose) were generally well tolerated. There is no experience with doses above 600mg in humans.
Management: In the event of an overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring and institute clinical measures if required.